Journal
CANCER TREATMENT REVIEWS
Volume 32, Issue 6, Pages 423-436Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2006.05.005
Keywords
pediatric osteosarcoma; chemotherapy; surgery; chemotherapy; new drugs
Categories
Ask authors/readers for more resources
The current combination treatment, chemotherapy and surgery, has significantly improved the cure rate and the survival rate of primary bone osteosarcoma. The 5-year survival rate has increased in the last 30 years from 10% to 70%. Even in patients with poor prognosis, such as those with metastases at diagnosis, the 5-year survival rate has reached 20-30% due to chemotherapy and the surgical removal of metastases and primary tumor. However, the most effective drugs are still the same as those employed over the last 20 years as front tine neoadjuvant or adjuvant chemotherapy: Doxorubicin, Cisplatin, Methotrexate, Ifosfamide. No standard, second tine therapy exists for those who relapse. At relapse, due to the tack of new non-cross-resistant drugs, surgery is still the main option when feasible. Other drugs have been employed in relapsed patients with poor results. This article reviews the state of the art of treatment for bone osteosarcoma in the pediatric age. (c) 2006 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available